Study Summary
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize (Mucin 1) MUC1 is safe and effective for patients with relapsed or refractory solid tumor.
Want to learn more about this trial?
Request More InfoInterventions
anti-MUC1 CAR T CellsBIOLOGICAL
No description available.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| PersonGen Biomedicine (Suzhou) Co., Ltd. | Suzhou | Jiangsu | China |